乳腺癌合并甲状腺癌患者的临床病理特征分析  

Clinical and pathological features of breast cancer with thyroid cancer

作　　者：商江峰[1] 吴旦平[1] 汪波[1] 宋佳[1] 顾芯烨 苏文捷[1] 孙凯律 杨志学[2] Shang Jiangfeng;Wu Danping;Wang Bo;Song Jia;Gu Xinye;Su Wenjie;Sun Kailu;Yang Zhixue(The First People’s Hospital of Changshu, Changshu 215500, China;The Second Affiliated Hospital of Suzhou University, Suzhou 210000, China)

机构地区：[1]江苏省常熟市第一人民医院,常熟215500 [2]苏州大学附属第二医院,苏州210000

出　　处：《广西医科大学学报》2019年第6期919-923,共5页Journal of Guangxi Medical University

摘　　要：目的:研究乳腺癌合并甲状腺癌患者的临床病理特征。方法:收集80例乳腺癌合并甲状腺癌患者(乳腺癌合并甲状腺癌组)及50例单纯乳腺癌患者(单纯乳腺癌组)的临床资料。将乳腺癌与甲状腺癌诊断时间相隔≤6个月患者纳入同时组(n=24),将乳腺癌与甲状腺癌诊断时间相隔>6个月患者纳入异时组(n=56)。对所有患者进行为期4年的随访,统计患者无病生存(DFS)情况。结果:乳腺癌合并甲状腺癌组雌激素受体(ER)阳性率、孕激素受体(PR)阳性率、人表皮生长因子受体-2(HER-2)阴性率显著高于单纯乳腺癌组(P<0.05)。在随访期间,乳腺癌合并甲状腺癌组复发转移9例,死亡3例;单纯乳腺癌组复发转移3例,死亡1例,两组DFS的生存曲线比较,差异有统计学意义(P<0.05)。在随访期间,同时组复发转移5例,死亡2例;异时组复发转移4例,死亡1例,两组DFS的生存曲线比较,差异有统计学意义(P<0.05)。结论:ER阳性、PR阳性、HER-2阴性的乳腺癌患者具有更高罹患甲状腺癌的概率,乳腺癌合并甲状腺癌可能增加疾病进展、局部复发和远处转移风险。Objective: To study the clinical and pathological features of breast cancer with thyroid cancer. Methods: The clinical data from 80 patients with breast cancer combined with thyroid cancer and 50 patients with simple breast cancer were collected. Patients were divided into two groups based on the interval between diagnosis of breast cancer and thyroid carcinoma: group A (6 and less than 6 months, n =24) and group B (more than 6 months, n =56). All patients were followed up for 4 years and the disease free survival (DFS) was statistically analyzed. Results: The estrogen receptor (ER) positive rate, progesterone receptor (PR) positive rate and human epidermal growth factor receptor-2 (HER-2) negative rate in the breast cancer with thyroid cancer group were significantly higher than those in the simple breast cancer group ( P <0.05). There were 9 cases of recurrence and metastases and 3 patients died in the breast cancer with thyroid cancer group, while 3 cases of recurrence and metastases and 1 patient died in the simple breast cancer group during the follow-up period. A significant difference was noted in the DFS curve between the two groups ( P <0.05). There were 5 cases of recurrence and metastases and 2 patients died in the group A, while 4 cases of recurrence and metastases and 1 patient died in the group B during the follow-up period. There was also significant difference in the DFS curve between the two groups ( P <0.05). Conclusion: ER positive, PR positive and HER-2 negative patients with breast cancer have higher risk of thyroid cancer. Breast cancer combined with thyroid cancer may increase the risks of disease progression, local recurrence and distal metastasis.

关 键 词：乳腺癌 甲状腺癌 双原发癌 特征 

分 类 号：R736.1[医药卫生—肿瘤]